VectivBio AG
$1.5M 10 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Cordis US Corp.
Cordis US Corp. reported $1,507,303.50 across General Payments, Research, and Ownership to 2,469 physicians and teaching hospitals across 2,487 transactions.
- $1.5M Above-median payer
- All-tracks total
- 2,487 Top quartile volume
- Transactions
- 2,469 Top quartile reach
- Recipients
- +$209.5K
- General Payments vs PY2023
Cordis US Corp. reported $1,507,303.50 across all CMS Open Payments tracks (General + Research + Ownership) to 2,469 physicians and teaching hospitals in Program Year 2024 - ranking #524 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,465,285.04, averaging $610.49 per recipient.
How Cordis US Corp.'s $1.5M all-tracks total breaks down
Cordis US Corp.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
40/100
Total payments
F
24/100
Transaction volume
F
28/100
Physician reach
F
29/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer cordis-us-corp Cordis US Corp.
$1.5M · #524/1,925 · 0.0% industry · PY2024
- TOT $1.5M
- RANK #524
- SHARE 0.0%
- TXN 2,487
- RCP 2,469
- CAT 6
- GEN $1.5M
- ΔGEN +$209.5K
- TOP1 53.8%
- PY 2024
Volume peers
Nearest volume peer: VectivBio AG ($1.5M)
Cordis US Corp. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Cordis US Corp.'s CMS-reported General Payments increased by $209.5K (+16.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CORDIS US CORP.PY2023: CORDIS US CORP.PY2024: CORDIS US CORP.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,255,814.38
- PY2024
- $1,465,285.04
What the Data Shows for Cordis US Corp.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Cordis US Corp., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
92 transactions worth $977.4K make "Consulting Fee" the top general-payment category in the 6-category breakdown below, 66.7% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 6 types of general payments, Cordis US Corp.'s largest category was "Consulting Fee" at $977.4K - 66.7% of General Payments.
Cordis US Corp. reports 6 general-payment categories - the top three are Consulting Fee (66.7%), Space Rental or Facility Fees (18.5%), and Grant (6.1%). The remaining 3 categories make up 8.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Cordis US Corp. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $977.4K | 92 | 66.7% |
| Space Rental or Facility Fees | $270.5K | 17 | 18.5% |
| Grant | $90.0K | 4 | 6.1% |
| Food and Beverage | $76.0K | 2,219 | 5.2% |
| Travel and Lodging | $51.3K | 133 | 3.5% |
| Education | $93.47 | 4 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,170,698.77 (79.9%) of $1,465,285.04 in this company's General Payments records across 1,548 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Cordis US Corp.
The five named recipients with the highest reported General Payments from this company
- 1
George Adams
$788,568.88 across 22 reported transactions
- 2
Washington Hospital Center
$267,000.00 across 9 reported transactions
- 3
Cleveland Clinic Hospital
$66,000.00 across 4 reported transactions
- 4
Mahmoud Malas
$33,962.95 across 4 reported transactions
- 5
Joseph Bumgarner
$15,166.94 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Cordis US Corp.'s spend rank (#524 of 1,925, top 27% by spend) and concentration rank (#539 of 1,838, top 29% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Menarini Silicon Biosystems, Inc. : $251.9K total payments, HHI 3287
- Grace Medical, Inc. : $46.8K total payments, HHI 3285
- Secura Bio, Inc. : $95.6K total payments, HHI 3279
- BeiGene, Ltd. : $222.0K total payments, HHI 3277
- Axis Spine Technologies Inc. : $26.4K total payments, HHI 3274
- Amplitude Vascular Systems, Inc. : $82.5K total payments, HHI 3271
- Cordis US Corp. (this company) : $1.5M total payments, HHI 3261
- Arbutus Medical, Inc : $64.9K total payments, HHI 3238
- Acuity Surgical Devices, LLC : $196.1K total payments, HHI 3232
- Centerline Biomedical Inc. : $564.5K total payments, HHI 3229
- Carbofix Spine Inc : $52.0K total payments, HHI 3217
- ICU Medical Inc : $55.8K total payments, HHI 3209
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Cordis US Corp.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Cordis US Corp..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Cordis US Corp..
Showing 6 of 1,924 companies with CMS-reported payment data.
Vital Connect, Inc
$1.5M 832 recipients
Compare payment profiles
Artivion, Inc.
$1.5M 1,638 recipients
Compare payment profiles
Fresenius Kabi USA, LLC
$1.5M 8,126 recipients
Compare payment profiles
ExThera Medical Corporation
$1.5M 15 recipients
Compare payment profiles
CardioFocus, Inc.
$1.5M 202 recipients
Compare payment profiles
Put this to use
Cordis US Corp. ranks #524 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Cordis US Corp. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Cordis US Corp.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.